Born in the Sonoran Desert, Devreux Sciences embeds clinical research within the practices where care already lives — bringing tomorrow's therapies to the patients of today, and producing data that earns its trust.
An Integrated Research Organization unites sponsors, investigators, and study participants within a single operational framework, removing the friction that traditionally separates trial demand from community-based care delivery.
Accelerated site qualification, protocol-matched enrollment from diverse populations, and inspection-ready source documentation across all phases of execution.
We assume the regulatory, contractual, and operational responsibilities of clinical research, allowing investigators to maintain focus on patient care while contributing to the evidence base.
Access to investigational therapies through a familiar care setting, with informed consent practices, dedicated coordination, and protocol-compliant subject support.
Devreux operates inside the practices where patients already receive care. This proximity to clinical workflow accelerates enrollment, improves retention, and produces source documentation that reflects authentic patient experience rather than research-only encounters.
Investigator Site Files, training documentation, and source records are maintained to a standard that allows immediate review by FDA inspectors, sponsor monitors, or independent auditors. We build for scrutiny because the cost of remediation always exceeds the cost of doing it correctly the first time.
Our operating model is anchored to the standards FDA and sponsor monitors evaluate during routine and for-cause inspections, not to vanity metrics that obscure execution risk.
Site qualification visits, master clinical trial agreement frameworks, and pre-positioned regulatory documentation enabling activation within sponsor-required timelines, typically four weeks from CDA execution.
Qualified principal investigators meeting FDA Form 1572 requirements, with documented delegation of authority, on-call availability for safety events, and continuous oversight of protocol adherence.
Electronic source documentation systems compliant with 21 CFR Part 11, real-time source data verification, and continuous audit trail integrity meeting ALCOA+ principles.
IRB-approved recruitment materials and broad enrollment reach across the Phoenix metropolitan region, paired with retention programs designed to meet contracted enrollment commitments.
Central and local IRB submission management, financial disclosure under 21 CFR Part 54, expedited safety reporting, and ongoing protocol amendment governance.
Continuous inspection readiness aligned to FDA Bioresearch Monitoring Program standards, with regulatory binders, training records, and source documents maintained for immediate review.
We focus where protocol complexity, recruitment difficulty, and operational specialization most directly determine trial success. New therapeutic areas are added to support sponsor-specific programs.
Phase II–IV programs in advanced heart failure, novel lipid-modifying therapies, and structural heart device studies, supported by access to cardiac imaging and procedural capabilities.
Diabetic foot ulcer therapeutics, advanced wound care interventions, and lower-extremity device evaluations conducted by board-certified podiatric investigators.
Inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, and functional GI trials with access to endoscopic and biopsy support for protocol-required procedures.
Chronic obstructive pulmonary disease, severe asthma biologics, and interstitial lung disease research supported by access to pulmonary function testing infrastructure.
+ Additional therapeutic areas onboarded per sponsor protocol — contact for capability expansion
Activation speed is meaningful only if the data holds up under any standard of regulatory scrutiny.
We measure ourselves not by how quickly we open a study, but by how cleanly we close one.
Research belongs inside clinical practice, not adjacent to it.
The participant's experience is part of the protocol, not separate from it.
A source document should be ready for any reviewer, on any day, without preparation.
From feasibility through database lock, every service is delivered by the same senior leadership, eliminating handoffs that introduce risk into the conduct of the study.
Protocol feasibility assessment, sponsor budget and contract negotiation, regulatory submission packet preparation, and accelerated activation aligned to enrollment timelines.
End-to-end study coordination, source data verification, sponsor monitoring support, and 24/7 principal investigator oversight for inpatient and complex outpatient protocols.
IRB submission management, expedited safety reporting under 21 CFR 312.32, financial disclosure tracking, and IRB-approved recruitment strategy execution.
Whether you are a sponsor evaluating site capabilities, an investigator exploring research integration, or a prospective participant inquiring about trial access, we welcome the conversation.